However, the largest Phase IIb trial involving 536 subjects failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading Metabolic Pharmaceuticals to terminate development in 2007
McGuire MJ, Ishii M (2016) Leptin dysfunction and Alzheimers disease: evidence from cellular, animal, and human studies
Then, one nonviruliferous virgin female was mated with one viruliferous male adult microinjected with Pelo or pre-immune antibody for 3 days
Central role of microglia in sepsis-associated encephalopathy: From mechanism to therapy
This approach more closely mimics the body's natural, rhythmic release, creating distinct peaks and troughs in hormone levels
Potential risks including bruising, vein irritation, fluid overload, or rare allergic reactions are discussed during consultation, and suitability is confirmed before treatment